ArticleJournal of renal injury prevention2016
The effect of lactulose supplementation on fecal microflora of patients with chronic kidney disease; a randomized clinical trial.
Article in Journal of renal injury prevention, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05934552 (Assesment of Lactulose vs Lactobacillus Acidophilus Effect in CKD Patients), which is not on this map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assesment of Lactulose vs Lactobacillus Acidophilus Effect in CKD Patients
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Pooled it
- Efficacy of probiotics/synbiotics supplementation in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.Frontiers in nutrition · 2024Pooled it
- Synbiotics, prebiotics and probiotics for people with chronic kidney disease.The Cochrane database of systematic reviews · 2023Pooled it
- Gastrointestinal Microbiota in Patients with Chronic Kidney Disease: A Systematic Review.Advances in nutrition (Bethesda, Md.) · 2019Pooled it
- Trial
- Microbiota stability in healthy individuals after single-dose lactulose challenge-A randomized controlled study.PloS one · 2018Trial
- LactuloseWorld journal of nephrology · 2026Article
- Impact of Probiotics, Prebiotics and Synbiotics Supplementation in Chronic Kidney Disease: A Comprehensive Review of Clinical Trials.Nutrients · 2026Review
- Gut microbiome-targeted therapeutics for chronic kidney disease: comparative efficacy of probiotic and microbial preparations.Inflammopharmacology · 2025Article
- The Gut-Kidney Axis in Chronic Kidney Diseases.Diagnostics (Basel, Switzerland) · 2024Review
- Pharmacologic Treatment of Chronic Constipation.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Review
- Real-world evidence of constipation and laxative use in the Korean population with chronic kidney disease from a common data model.Scientific reports · 2024Observational
- The Kidney-Gut Axis as a Novel Target for Nutritional Intervention to Counteract Chronic Kidney Disease Progression.Metabolites · 2024Review
- Commentary: Efficacy of probiotics/synbiotics supplementation in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.Frontiers in nutrition · 2024Article
- Gutted: constipation in children with chronic kidney disease and on dialysis.Pediatric nephrology (Berlin, Germany) · 2023Review
- Constipation in Patients With Chronic Kidney Disease.Journal of neurogastroenterology and motility · 2023Review
- The Gut-Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics.Life (Basel, Switzerland) · 2023Review
- Clinical Perspectives of Gut Microbiota in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: Where Do We Stand?Biomedicines · 2023Review
- The Impact of Renal Function on Hepatic Encephalopathy Following TIPS Placement for Refractory Ascites.Biomedicines · 2023Article
- 2022 Seoul Consensus on Clinical Practice Guidelines for Functional Constipation.Journal of neurogastroenterology and motility · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLactulose is a prebiotic with bifidogenic and urea reduction effects. It can improve Bifidobacteria and Lactobacilli counts in healthy humans and it may possibly have similar effects in chronic kidney disease (CKD) patients.
objectivesTo investigate the effect of lactulose on fecal microflora of patients with CKD. PATIENTS AND
methodsThirty-two patients with stages 3 and 4 of CKD (43.8% male with mean age of 58.09±12.75 years) were randomly assigned to intervention (n=16) and control (n=16) groups. Patients in intervention group received 30 mm lactulose syrup three times a day for an 8-week period. Control group received placebo 30 mm three times a day. A fecal sample was obtained from all patients at the beginning and at the end of the study and Bifidobacteria and Lactobacilli was counted.
resultsCreatinine (Cr) significantly decreased in intervention group (3.90±1.43 to 3.60±1.44, P=0.003) and increased in control group (3.87±2.08 to 4.11±1.99, P=0.03). Although Bifidobacterial and Lactobacilli counts were similar before intervention, they were significantly higher at the end of the study in lactulose group (P=0.01 and P=0.04, respectively). Lactulose led to significant increase in fecal Bifidobacterial counts (3.61±0.54 to 4.90±0.96, P<0.001) and Lactobacilli counts (2.79±1.00 to 3.87±1.13, P<0.001), while the change in placebo group was not significant.
conclusionLactulose administration will increase Bifidobacteria and Lactobacillus counts in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.